Evidence map›Paper›PMID 37990433›Full record

ReviewCurrent protein & peptide science2024

Development and Challenges of Cyclic Peptides for Immunomodulation.

Xianqiong Jiang, Li Gao, Zhilong Li, Yan Shen, Zhi-Hua Lin

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current protein & peptide science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Xianqiong JiangSchool of Pharmacy and Bioengineering, Chongqing University of Technology, 405400 Chongqing, China.
Li GaoSchool of Pharmacy and Bioengineering, Chongqing University of Technology, 405400 Chongqing, China.
Zhilong LiSchool of Pharmacy and Bioengineering, Chongqing University of Technology, 405400 Chongqing, China.
Yan ShenSchool of Pharmacy and Bioengineering, Chongqing University of Technology, 405400 Chongqing, China.
Zhi-Hua LinSchool of Pharmacy and Bioengineering, Chongqing University of Technology, 405400 Chongqing, China.
Chongqing University of Technology · CNChongqing University · CN

Funding

National Natural Science Foundation of China (NSFC) Grant no. 82100684
6 · The paper itself

Abstract

Cyclic peptides are polypeptide chains formed by cyclic sequences of amide bonds between protein-derived or non-protein-derived amino acids. Compared to linear peptides, cyclic peptides offer several unique advantages, such as increased stability, stronger affinity, improved selectivity, and reduced toxicity. Cyclic peptide has been proved to have a promising application prospect in the medical field. In addition, this paper mainly describes that cyclic peptides play an important role in anti-cancer, anti-inflammatory, anti-virus, treatment of multiple sclerosis and membranous nephropathy through immunomodulation. In order to know more useful information about cyclic peptides in clinical research and drug application, this paper also summarizes cyclic peptides currently in the clinical trial stage and cyclic peptide drugs approved for marketing in the recent five years. Cyclic peptides have many advantages and great potential in treating various diseases, but there are still many challenges to be solved in the development process of cyclic peptides.

Indexed as

Peptides, CyclicAnimalsAnti-Inflammatory AgentsAntineoplastic AgentsAntiviral AgentsClinical Trials as TopicHumansImmunologic FactorsImmunomodulating AgentsImmunomodulationMultiple SclerosisAnti-Inflammatory AgentsAntineoplastic AgentsAntiviral AgentsImmunologic FactorsImmunomodulating AgentsPeptides, Cyclicanti-inflammatoryCyclic peptidesimmunity mechanismsimmunomodulationmultiple sclerosis.pharmacological activities

Identifiers

PMID37990433
OpenAlexW4388910690

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.